Eugene Hwang

Dr. Eugene Hwang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2012 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
EHEugene Hwang
Eugene Hwang
RJRegina I. Jakacki
Regina I. Jakacki
MFMichael J. Fisher
Michael J. Fisher
LKLindsay B. Kilburn
Lindsay B. Kilburn
MHMarianna Horn
Marianna Horn
RPRoger J. Packer
Roger J. Packer

20 January 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
EHEugene Hwang
Eugene Hwang
ESElias J. Sayour
Elias J. Sayour
CFCatherine T. Flores
Catherine T. Flores
GGGerald Grant
Gerald Grant
RWRobert Wechsler-Reya
Robert Wechsler-Reya
IPIan F. Pollack
Ian F. Pollack

20 July 2016 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
NDN. Drezner
N. Drezner
KHK. K. Hardy
K. K. Hardy
EWE. Wells
E. Wells
GVG. Vezina
G. Vezina
CHC. Y. Ho
C. Y. Ho
EHEugene Hwang
Eugene Hwang

20 March 2023 in Neoplasia
Verified
Journal Article
Open access
EHEugene Hwang
Eugene Hwang
DHDerek Hanson
Derek Hanson
MFMariella G. Filbin
Mariella G. Filbin
SMStephen C. Mack
Stephen C. Mack
Pediatric intracranial ependymoma has seen a recent exponential expansion of biological findings, rapidly dividing the diagnosis into several subgroups, each with specific molecular and clinical characteristics. While such subdivision may complicate clinical conclusions from historical trials, this knowledge also provides an opportunity for interrogating the major clinical and biological questions preventing near-term translation into effective therapy for children with ependymoma. In this article, we briefly review some of the most critical clinical questions facing both patient management and the construct of future trials in childhood ependymoma, as well as explore some of the current barriers to efficient translation of preclinical discovery to the clinic.

3 December 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
ALAudrey-Anne Lamoureux
Audrey-Anne Lamoureux
MFMichael J. Fisher
Michael J. Fisher
LLLauriane Lemelle
Lauriane Lemelle
EPElke Pfaff
Elke Pfaff
PAPouneh Amir-Yazdani
Pouneh Amir-Yazdani
Sébastien PerreaultSébastien Perreault
Sébastien Perreault
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults (P < 0.0001). Patients with LGG also had a better outcome when compared with HGG (P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.

10 October 2019 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
AJAlok Jaju
Alok Jaju
EHEugene Hwang
Eugene Hwang
MKM. Kool
M. Kool
DCDavid Capper
David Capper
LCL. Chavez
L. Chavez
LHL.A. Heier
L.A. Heier
BACKGROUND AND PURPOSE: Supratentorial primitive neuroectodermal tumors and pineoblastomas have traditionally been grouped together for treatment purposes. Molecular profiling of these tumors has revealed a number of distinct entities and has led to the term “CNS-primitive neuroectodermal tumors” being removed from the 2016 World Health Organization classification. The purpose of this study was to describe the MR imaging findings of histologically diagnosed primitive neuroectodermal tumors and pineoblastomas and correlate them with molecular diagnoses and outcomes. MATERIALS AND METHODS: Histologically diagnosed primitive neuroectodermal tumors and pineoblastomas were enrolled in this Children’s Oncology Group Phase III trial, and molecular classification was retrospectively completed using DNA methylation profiling. MR imaging features were systematically studied and correlated with molecular diagnoses and survival. RESULTS: Of the 85 patients enrolled, 56 met the inclusion criteria, in whom 28 tumors were in pineal and 28 in nonpineal locations. Methylation profiling revealed a variety of diagnoses, including pineoblastomas (n = 27), high-grade gliomas (n = 17), embryonal tumors (n = 7), atypical teratoid/rhabdoid tumors (n = 3), and ependymomas (n = 2). Thus, 39% overall and 71% of nonpineal tumor diagnoses were discrepant with histopathology. Tumor location, size, margins, and edema were predictors of embryonal-versus-nonembryonal tumors. Larger size and ill-defined margins correlated with poor event-free survival, while metastatic disease by MR imaging did not. CONCLUSIONS: In nonpineal locations, only a minority of histologically diagnosed primitive neuroectodermal tumors are embryonal tumors; therefore, high-grade glioma or ependymoma should be high on the radiographic differential. An understanding of molecularly defined tumor entities and their relative frequencies and locations will help the radiologist make more accurate predictions of the tumor types.